Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Sierra Oncology Inc (SRRA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 172,399
  • Shares Outstanding, K 74,310
  • Annual Sales, $ 0 K
  • Annual Income, $ -42,020 K
  • 36-Month Beta 2.37
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.32

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.81 +32.60%
on 04/26/18
2.95 -18.64%
on 05/18/18
+0.57 (+31.15%)
since 04/25/18
3-Month
1.77 +35.59%
on 04/25/18
3.03 -20.79%
on 02/26/18
-0.58 (-19.46%)
since 02/23/18
52-Week
1.10 +118.18%
on 06/19/17
4.09 -41.32%
on 12/27/17
+1.20 (+100.00%)
since 05/25/17

Most Recent Stories

More News
Free Research Reports on Sorrento Therapeutics and Three More Biotech Stocks

Stock Research Monitor: SRRA, ONCE, and SPPI

SRNE : 7.85 (-1.26%)
ONCE : 78.39 (-0.80%)
SRRA : 2.40 (+3.45%)
Sierra Oncology Reports First Quarter Results

SRA737 Monotherapy Phase 1/2 trial expanded to enroll CCNE1-driven ovarian cancer cohort - - SRA737 Low-Dose Gemcitabine Combination Phase 1/2 trial advanced into cohort expansion phase - - $133.8 million...

SRRA : 2.40 (+3.45%)
Sierra Late-Breaking Data Demonstrating SRA737 Preclinical Activity with PARPi to be Presented at the AACR 2018 Annual Meeting

Sierra Late-Breaking Data Demonstrating SRA737 Preclinical Activity with PARPi to be Presented at the AACR 2018 Annual Meeting

SRRA : 2.40 (+3.45%)
Sierra Oncology to Present at the Future Leaders in the Biotech Industry Conference in New York

Sierra Oncology to Present at the Future Leaders in the Biotech Industry Conference in New York

SRRA : 2.40 (+3.45%)
Pre-Market Technical Scan on Biotech Equities -- Riot Blockchain, Sage Therapeutics, Sarepta Therapeutics, and Sierra Oncology

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on RIOT, SAGE, SRPT, and SRRA which can be accessed for free by signing up to www.wallstequities.com/registration....

SRPT : 91.65 (+1.84%)
SRRA : 2.40 (+3.45%)
RIOT : 7.59 (-2.57%)
SAGE : 155.33 (-1.80%)
Late-Breaking Abstract Reporting SRA737 Preclinical Activity in CCNE1-Driven and PARPi-Resistant Cancers Accepted for AACR 2018 Annual Meeting

Late-Breaking Abstract Reporting SRA737 Preclinical Activity in CCNE1-Driven and PARPi-Resistant Cancers Accepted for AACR 2018 Annual Meeting

SRRA : 2.40 (+3.45%)
Sierra Oncology Announces Pricing of Public Offering of Common Stock

Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response therapeutics for the treatment of patients with cancer, today announced...

SRRA : 2.40 (+3.45%)
Sierra Oncology Announces Proposed Public Offering of Common Stock

Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response therapeutics for the treatment of patients with cancer, today announced...

SRRA : 2.40 (+3.45%)
Sierra Oncology Significantly Expands Clinical Development Program

Ongoing SRA737 clinical studies expanded to target aggregate enrollment of 200 patients across ten cancer indications -- Adding new SRA737 monotherapy cohort for CCNE1-driven ovarian cancer -- SRA141 IND...

SRRA : 2.40 (+3.45%)
Sierra Oncology and Janssen Sign Supply Agreement for Prostate Cancer Study

Janssen to supply PARP inhibitor niraparib for Sierra's Phase 1b/2 combination trial with Chk1 inhibitor SRA737 -

SRRA : 2.40 (+3.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade SRRA with:

Business Summary

Sierra Oncology, Inc. is a clinical-stage drug development company. It develops and markets drugs for the treatment of cancer. The product pipeline consists of SRA737 and SRA141. SRA737 is an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, a key cell cycle checkpoint and central...

See More

Key Turning Points

2nd Resistance Point 2.53
1st Resistance Point 2.47
Last Price 2.40
1st Support Level 2.32
2nd Support Level 2.23

See More

52-Week High 4.09
Fibonacci 61.8% 2.95
Fibonacci 50% 2.60
Last Price 2.40
Fibonacci 38.2% 2.24
52-Week Low 1.10

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar